Vertex Pharmaceuticals Director Daniel J. Brennan Receives 795 RSUs
VERTEX PHARMACEUTICALS INC / MA
Subscribe to track VRTX
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
📋 Form 4 Filing: Vertex Pharmaceuticals Inc ($VRTX) Insider: Daniel J. Brennan (Director) Transaction: Award / Grant (Code: A) Shares: 795 @ $503.47 (~$400,259) Post-Transaction Holdings: 795 shares Significance: Low (Routine Director RSU Grant)
Comprehensive Analysis
Executive Summary
On October 22, 2026, Vertex Pharmaceuticals Inc ($VRTX) filed a Form 4 reporting that Director Daniel J. Brennan was granted 795 restricted stock units (RSUs) on October 20, 2026. The transaction represents standard director compensation.
Transaction Details
- Insider: Daniel J. Brennan
- Role: Director
- Date of Transaction: October 20, 2026
- Security: Common Stock (RSUs)
- Transaction Code: A (Grant/Award)
- Shares Acquired: 795
- Grant Price Reference: $503.47 per share
- Total Notional Value: $400,258.65
- Beneficial Ownership Following Transaction: 795 shares (Direct)
Terms and Vesting
Per footnote (1), the restricted stock units vest on the first anniversary of the grant date, subject to specific limited exceptions.
Market Impact & Significance
This transaction carries Low informational significance for investors as it constitutes an ordinary-course equity grant as part of board compensation rather than an open-market purchase or sale.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.